Elon Musk’s DOGE Point Man is Now An MDMA Consigliere

Antonio Gracius, Elon Kastor’s close ally and Tesla (TSLA) Member of the Board, has been the pioneer in one Controversial techover A biotech firm that developed MDMA-based therapy is once rejected for protection anxiety by developed MDMA-based therapy ReportThe

As the cycadelix industry is inch towards mainstream acceptance, new development reveals how politics, science and industry interests are making the future of mental health treatment.

However, the regulatory body of the company he is now increasing is increasing the eyebrows of Gracius, the eyebrows. Parents Report.

Lickos, which early this year announced the Million 50 million rebuilding, is in front of some of the most committed research on therapy in MDMA-help. However the rejection of the recent FDA’s clinical trials of the firm, which quoted Error associated with bias and trial designHas expressed doubts about the possibility of approval.

Basically thanks to the debate about scientific stiffness, the organization has ordered Test 3 new phaseSuch a process may probably take years and can spend a few million.

Opponents of the organization argued that faulty science leads to rejection, while supporters believe the possibility of MDMA treatment under proper control.

Lycos or Gracius nobody responds to the request for the comment.

‘Chakas Grizing’ for control?

Gracius’ lately Leocos, hedge funds and wealthy investors, with wealthy investors, with $ 50 million infusion, Republicans and Democratic officials are warming the idea of ​​rapid approval for cyclic drugs.

Some of the top health officials of the Trump-era, such as former officers and lawmakers, Has publicly supported Referring to the initial results and the patient’s needs, the regulatory process is to be rebuilt.

It is raising the alarm bell with ethics experts.

“You can’t do the wheels and then you can’t say, ‘Okay, now I’m going to chase that approval,” said Cynthia Brown, a senior ethics consultant to citizens of Washington’s non -profit Watchdog Group, Told the GuardianThe

This political support fuel the concern about science to politics. Critics warned that FDA standards under the influence of industrial interiors could reduce the integrity of scientific research or fast tracking approval, if compromised with protection, could make the future catastrophe risky.

“The challenge is confirmed that the enthusiasm does not exceed the proof,” as Mason Marx, Professor of Harvard Law, expert in drug policy, Told the GuardianThe “Science must be independent of politics to avoid the unpleasant of the whole industry.”

Meanwhile, the relationship with Grasius’s musk and military forces has raised questions about the conflict of interest in the government, including its past work, and the regulatory reforms in the government.

So will the FDA revisit now?

The FDA is now a wide range of discretion to issue an emergency approval or quick review of its previous decisions, creating opportunities to accelerate their paths in the market.

“Map and Gracius are going to try to occupy the moment we’re at the moment we are,” Ephitayo Harvey, a former map employee and executive director of The People’s Psychiedelic Collective, Dr. “I think the goal is to be approved in any way required by Psychotherapy FDA in MDMA-Help.”

The involvement of Gracius raises a number of questions for the Burdwan psydevilics industry.

It stands at a intersection: whether the politician is proceeded under committed conditions or to proceed cautiously to ensure long -term protection and effectiveness. Since political personality deepens the public interest towards mental health and wellness, art interior and controllers face a subtle balance between hope and loss, progress and prudence.

“With the lack of transparency, it means what it means to be Dog,” Fith Williams says, a non -profit watchdog group, policy director of government supervision project, Tell the Guardian.The “We have seen many people, if there is no conflict of interest, there is a possibility of conflict of interest and if corruption is not the possibility of complete corruption.”

The magic of burning man

Rick Dublin, the founder and president of the Multidcylinary Association (MAPS) for psychicidalic studies and a prominent, long -time lawyer for the research and treatment use of psychidic drugs. W. said that he immediately saw a partnership.

“It was the magic of the burning man,” Dublin Dr. “I was looking for a white knight that would come and more focus on healing and public advantages.”

In that spring, Lycos Therapeutics appointed a new CEO and Chief Medical Officer and reorganized its board of directors and announced a large leadership shackup. These steps were present as control as Graceius and investor Christopher Han control.

“Actively involved in the Daily Operations of the Gracius Company,” the inherent of the nameless map director and the art of art, ” Tell the Guardian. They said that Gracius was now emphasizing the impact on the farm’s strategic direction because it aims to regain control of regulatory confidence and accelerate clinical trials.

This leadership shift refers to the interest of a higher partner and intense industry in psychidolics, supporters and critics are similarly monitored as the company navigates complex regulators and scientific barriers.

However, more abnormally, supporters of the company have been accused of an attempt to raise a fund that is involved in drugs with investors.

“Certainly a part of their fundraising strategy is to ‘meet the rich in the burning man, do psychadellics with them and get the map,” “Harvey, who was Dublin’s executive assistant in the 21st, Tell the Guardian.

Map adds to the allegations of drugs with investors

Maps have denied that it used drugs as a means of druming in investment.

“Maps conduct all funding activities with maximum integrity and maintain strict moral boundaries in all donor relationships and fundraising activities. Maps do not provide controlled substances to any events or deposits, or we do not use substance as fundraising equipment or techniques,” the map says in a statement.

Dublin Last year told Business Insider Donor medicines were “not common”.